カテゴリー： Market Monitor Global, 世界, 医療/バイオ

神経疾患治療薬の世界市場見通し2023年-2029年

◆英語タイトル：Neurologic Disorder Treatment Drug Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23JU5803）◆商品コード：MMG23JU5803
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年6月
◆ページ数：104
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医薬品＆医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Neurologic Disorder Treatment Drug Market 調査レポートは次の情報を含め、グローバルにおけるの神経疾患治療薬市場規模と予測を収録しています。・世界の神経疾患治療薬市場：売上、2018年-2023年、2024年-2029年
・世界の神経疾患治療薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の神経疾患治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「抗コリン薬」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

神経疾患治療薬のグローバル主要企業は、AbbVie、 Acadia Pharmaceuticals、 Acorda Therapeutics Biotechnology、 Bayer、 Biogen、 CSK、 Eisai、 F. Hoffmann La Roche、 H Lundbeck、 Johnson and Johnson、 Merck、 Novartis、 Otsuka Pharmaceutical、 Pfizer、 Sanofi、 Takeda Pharmaceutical、 Teva Pharmaceutical Industries、 UCB、 USWMなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、神経疾患治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界の神経疾患治療薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の神経疾患治療薬市場：タイプ別市場シェア、2022年
・抗コリン薬、抗てんかん薬、抗精神病薬、催眠鎮静薬、鎮痛薬、降圧薬、抗凝固薬、その他

世界の神経疾患治療薬市場：用途別、2018年-2023年、2024年-2029年
世界の神経疾患治療薬市場：用途別市場シェア、2022年
・てんかん、アルツハイマー病、パーキンソン病、多発性硬化症、脳血管疾患、その他

世界の神経疾患治療薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の神経疾患治療薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業における神経疾患治療薬のグローバル売上、2018年-2023年
・主要企業における神経疾患治療薬のグローバル売上シェア、2022年
・主要企業における神経疾患治療薬のグローバル販売量、2018年-2023年
・主要企業における神経疾患治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
AbbVie、 Acadia Pharmaceuticals、 Acorda Therapeutics Biotechnology、 Bayer、 Biogen、 CSK、 Eisai、 F. Hoffmann La Roche、 H Lundbeck、 Johnson and Johnson、 Merck、 Novartis、 Otsuka Pharmaceutical、 Pfizer、 Sanofi、 Takeda Pharmaceutical、 Teva Pharmaceutical Industries、 UCB、 USWM

*************************************************************

・調査・分析レポートの概要
神経疾患治療薬市場の定義
市場セグメント
世界の神経疾患治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の神経疾患治療薬市場規模
世界の神経疾患治療薬市場規模：2022年 VS 2029年
世界の神経疾患治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの神経疾患治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の神経疾患治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：抗コリン薬、抗てんかん薬、抗精神病薬、催眠鎮静薬、鎮痛薬、降圧薬、抗凝固薬、その他
神経疾患治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：てんかん、アルツハイマー病、パーキンソン病、多発性硬化症、脳血管疾患、その他
神経疾患治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別神経疾患治療薬市場規模 2022年と2029年
地域別神経疾患治療薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
AbbVie、 Acadia Pharmaceuticals、 Acorda Therapeutics Biotechnology、 Bayer、 Biogen、 CSK、 Eisai、 F. Hoffmann La Roche、 H Lundbeck、 Johnson and Johnson、 Merck、 Novartis、 Otsuka Pharmaceutical、 Pfizer、 Sanofi、 Takeda Pharmaceutical、 Teva Pharmaceutical Industries、 UCB、 USWM
...

This report aims to provide a comprehensive presentation of the global market for Neurologic Disorder Treatment Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurologic Disorder Treatment Drug. This report contains market size and forecasts of Neurologic Disorder Treatment Drug in global, including the following market information:
Global Neurologic Disorder Treatment Drug Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Neurologic Disorder Treatment Drug market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Anticholinergic Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Neurologic Disorder Treatment Drug include AbbVie, Acadia Pharmaceuticals, Acorda Therapeutics Biotechnology, Bayer, Biogen, CSK, Eisai, F. Hoffmann La Roche and H Lundbeck, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Neurologic Disorder Treatment Drug companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Neurologic Disorder Treatment Drug Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Neurologic Disorder Treatment Drug Market Segment Percentages, by Type, 2022 (%)
Anticholinergic
Antiepileptic
Antipsychotic
Hypnotic and Sedative
Analgesics
Antihypertensive
Anticoagulants
Others
Global Neurologic Disorder Treatment Drug Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Neurologic Disorder Treatment Drug Market Segment Percentages, by Application, 2022 (%)
Epilepsy
Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis
Cerebrovascular Disease
Others
Global Neurologic Disorder Treatment Drug Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Neurologic Disorder Treatment Drug Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Neurologic Disorder Treatment Drug revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Neurologic Disorder Treatment Drug revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
AbbVie
Acadia Pharmaceuticals
Acorda Therapeutics Biotechnology
Bayer
Biogen
CSK
Eisai
F. Hoffmann La Roche
H Lundbeck
Johnson and Johnson
Merck
Novartis
Otsuka Pharmaceutical
Pfizer
Sanofi
Takeda Pharmaceutical
Teva Pharmaceutical Industries
UCB
USWM
Outline of Major Chapters:
Chapter 1: Introduces the definition of Neurologic Disorder Treatment Drug, market overview.
Chapter 2: Global Neurologic Disorder Treatment Drug market size in revenue.
Chapter 3: Detailed analysis of Neurologic Disorder Treatment Drug company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Neurologic Disorder Treatment Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Neurologic Disorder Treatment Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Neurologic Disorder Treatment Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Neurologic Disorder Treatment Drug Overall Market Size
2.1 Global Neurologic Disorder Treatment Drug Market Size: 2022 VS 2029
2.2 Global Neurologic Disorder Treatment Drug Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Neurologic Disorder Treatment Drug Players in Global Market
3.2 Top Global Neurologic Disorder Treatment Drug Companies Ranked by Revenue
3.3 Global Neurologic Disorder Treatment Drug Revenue by Companies
3.4 Top 3 and Top 5 Neurologic Disorder Treatment Drug Companies in Global Market, by Revenue in 2022
3.5 Global Companies Neurologic Disorder Treatment Drug Product Type
3.6 Tier 1, Tier 2 and Tier 3 Neurologic Disorder Treatment Drug Players in Global Market
3.6.1 List of Global Tier 1 Neurologic Disorder Treatment Drug Companies
3.6.2 List of Global Tier 2 and Tier 3 Neurologic Disorder Treatment Drug Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Neurologic Disorder Treatment Drug Market Size Markets, 2022 & 2029
4.1.2 Anticholinergic
4.1.3 Antiepileptic
4.1.4 Antipsychotic
4.1.5 Hypnotic and Sedative
4.1.6 Analgesics
4.1.7 Antihypertensive
4.1.8 Anticoagulants
4.1.9 Others
4.2 By Type – Global Neurologic Disorder Treatment Drug Revenue & Forecasts
4.2.1 By Type – Global Neurologic Disorder Treatment Drug Revenue, 2018-2023
4.2.2 By Type – Global Neurologic Disorder Treatment Drug Revenue, 2024-2029
4.2.3 By Type – Global Neurologic Disorder Treatment Drug Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Neurologic Disorder Treatment Drug Market Size, 2022 & 2029
5.1.2 Epilepsy
5.1.3 Alzheimer’s Disease
5.1.4 Parkinson’s Disease
5.1.5 Multiple Sclerosis
5.1.6 Cerebrovascular Disease
5.1.7 Others
5.2 By Application – Global Neurologic Disorder Treatment Drug Revenue & Forecasts
5.2.1 By Application – Global Neurologic Disorder Treatment Drug Revenue, 2018-2023
5.2.2 By Application – Global Neurologic Disorder Treatment Drug Revenue, 2024-2029
5.2.3 By Application – Global Neurologic Disorder Treatment Drug Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Neurologic Disorder Treatment Drug Market Size, 2022 & 2029
6.2 By Region – Global Neurologic Disorder Treatment Drug Revenue & Forecasts
6.2.1 By Region – Global Neurologic Disorder Treatment Drug Revenue, 2018-2023
6.2.2 By Region – Global Neurologic Disorder Treatment Drug Revenue, 2024-2029
6.2.3 By Region – Global Neurologic Disorder Treatment Drug Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Neurologic Disorder Treatment Drug Revenue, 2018-2029
6.3.2 US Neurologic Disorder Treatment Drug Market Size, 2018-2029
6.3.3 Canada Neurologic Disorder Treatment Drug Market Size, 2018-2029
6.3.4 Mexico Neurologic Disorder Treatment Drug Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Neurologic Disorder Treatment Drug Revenue, 2018-2029
6.4.2 Germany Neurologic Disorder Treatment Drug Market Size, 2018-2029
6.4.3 France Neurologic Disorder Treatment Drug Market Size, 2018-2029
6.4.4 U.K. Neurologic Disorder Treatment Drug Market Size, 2018-2029
6.4.5 Italy Neurologic Disorder Treatment Drug Market Size, 2018-2029
6.4.6 Russia Neurologic Disorder Treatment Drug Market Size, 2018-2029
6.4.7 Nordic Countries Neurologic Disorder Treatment Drug Market Size, 2018-2029
6.4.8 Benelux Neurologic Disorder Treatment Drug Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Neurologic Disorder Treatment Drug Revenue, 2018-2029
6.5.2 China Neurologic Disorder Treatment Drug Market Size, 2018-2029
6.5.3 Japan Neurologic Disorder Treatment Drug Market Size, 2018-2029
6.5.4 South Korea Neurologic Disorder Treatment Drug Market Size, 2018-2029
6.5.5 Southeast Asia Neurologic Disorder Treatment Drug Market Size, 2018-2029
6.5.6 India Neurologic Disorder Treatment Drug Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Neurologic Disorder Treatment Drug Revenue, 2018-2029
6.6.2 Brazil Neurologic Disorder Treatment Drug Market Size, 2018-2029
6.6.3 Argentina Neurologic Disorder Treatment Drug Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Neurologic Disorder Treatment Drug Revenue, 2018-2029
6.7.2 Turkey Neurologic Disorder Treatment Drug Market Size, 2018-2029
6.7.3 Israel Neurologic Disorder Treatment Drug Market Size, 2018-2029
6.7.4 Saudi Arabia Neurologic Disorder Treatment Drug Market Size, 2018-2029
6.7.5 UAE Neurologic Disorder Treatment Drug Market Size, 2018-2029
7 Neurologic Disorder Treatment Drug Companies Profiles
7.1 AbbVie
7.1.1 AbbVie Company Summary
7.1.2 AbbVie Business Overview
7.1.3 AbbVie Neurologic Disorder Treatment Drug Major Product Offerings
7.1.4 AbbVie Neurologic Disorder Treatment Drug Revenue in Global Market (2018-2023)
7.1.5 AbbVie Key News & Latest Developments
7.2 Acadia Pharmaceuticals
7.2.1 Acadia Pharmaceuticals Company Summary
7.2.2 Acadia Pharmaceuticals Business Overview
7.2.3 Acadia Pharmaceuticals Neurologic Disorder Treatment Drug Major Product Offerings
7.2.4 Acadia Pharmaceuticals Neurologic Disorder Treatment Drug Revenue in Global Market (2018-2023)
7.2.5 Acadia Pharmaceuticals Key News & Latest Developments
7.3 Acorda Therapeutics Biotechnology
7.3.1 Acorda Therapeutics Biotechnology Company Summary
7.3.2 Acorda Therapeutics Biotechnology Business Overview
7.3.3 Acorda Therapeutics Biotechnology Neurologic Disorder Treatment Drug Major Product Offerings
7.3.4 Acorda Therapeutics Biotechnology Neurologic Disorder Treatment Drug Revenue in Global Market (2018-2023)
7.3.5 Acorda Therapeutics Biotechnology Key News & Latest Developments
7.4 Bayer
7.4.1 Bayer Company Summary
7.4.2 Bayer Business Overview
7.4.3 Bayer Neurologic Disorder Treatment Drug Major Product Offerings
7.4.4 Bayer Neurologic Disorder Treatment Drug Revenue in Global Market (2018-2023)
7.4.5 Bayer Key News & Latest Developments
7.5 Biogen
7.5.1 Biogen Company Summary
7.5.2 Biogen Business Overview
7.5.3 Biogen Neurologic Disorder Treatment Drug Major Product Offerings
7.5.4 Biogen Neurologic Disorder Treatment Drug Revenue in Global Market (2018-2023)
7.5.5 Biogen Key News & Latest Developments
7.6 CSK
7.6.1 CSK Company Summary
7.6.2 CSK Business Overview
7.6.3 CSK Neurologic Disorder Treatment Drug Major Product Offerings
7.6.4 CSK Neurologic Disorder Treatment Drug Revenue in Global Market (2018-2023)
7.6.5 CSK Key News & Latest Developments
7.7 Eisai
7.7.1 Eisai Company Summary
7.7.2 Eisai Business Overview
7.7.3 Eisai Neurologic Disorder Treatment Drug Major Product Offerings
7.7.4 Eisai Neurologic Disorder Treatment Drug Revenue in Global Market (2018-2023)
7.7.5 Eisai Key News & Latest Developments
7.8 F. Hoffmann La Roche
7.8.1 F. Hoffmann La Roche Company Summary
7.8.2 F. Hoffmann La Roche Business Overview
7.8.3 F. Hoffmann La Roche Neurologic Disorder Treatment Drug Major Product Offerings
7.8.4 F. Hoffmann La Roche Neurologic Disorder Treatment Drug Revenue in Global Market (2018-2023)
7.8.5 F. Hoffmann La Roche Key News & Latest Developments
7.9 H Lundbeck
7.9.1 H Lundbeck Company Summary
7.9.2 H Lundbeck Business Overview
7.9.3 H Lundbeck Neurologic Disorder Treatment Drug Major Product Offerings
7.9.4 H Lundbeck Neurologic Disorder Treatment Drug Revenue in Global Market (2018-2023)
7.9.5 H Lundbeck Key News & Latest Developments
7.10 Johnson and Johnson
7.10.1 Johnson and Johnson Company Summary
7.10.2 Johnson and Johnson Business Overview
7.10.3 Johnson and Johnson Neurologic Disorder Treatment Drug Major Product Offerings
7.10.4 Johnson and Johnson Neurologic Disorder Treatment Drug Revenue in Global Market (2018-2023)
7.10.5 Johnson and Johnson Key News & Latest Developments
7.11 Merck
7.11.1 Merck Company Summary
7.11.2 Merck Business Overview
7.11.3 Merck Neurologic Disorder Treatment Drug Major Product Offerings
7.11.4 Merck Neurologic Disorder Treatment Drug Revenue in Global Market (2018-2023)
7.11.5 Merck Key News & Latest Developments
7.12 Novartis
7.12.1 Novartis Company Summary
7.12.2 Novartis Business Overview
7.12.3 Novartis Neurologic Disorder Treatment Drug Major Product Offerings
7.12.4 Novartis Neurologic Disorder Treatment Drug Revenue in Global Market (2018-2023)
7.12.5 Novartis Key News & Latest Developments
7.13 Otsuka Pharmaceutical
7.13.1 Otsuka Pharmaceutical Company Summary
7.13.2 Otsuka Pharmaceutical Business Overview
7.13.3 Otsuka Pharmaceutical Neurologic Disorder Treatment Drug Major Product Offerings
7.13.4 Otsuka Pharmaceutical Neurologic Disorder Treatment Drug Revenue in Global Market (2018-2023)
7.13.5 Otsuka Pharmaceutical Key News & Latest Developments
7.14 Pfizer
7.14.1 Pfizer Company Summary
7.14.2 Pfizer Business Overview
7.14.3 Pfizer Neurologic Disorder Treatment Drug Major Product Offerings
7.14.4 Pfizer Neurologic Disorder Treatment Drug Revenue in Global Market (2018-2023)
7.14.5 Pfizer Key News & Latest Developments
7.15 Sanofi
7.15.1 Sanofi Company Summary
7.15.2 Sanofi Business Overview
7.15.3 Sanofi Neurologic Disorder Treatment Drug Major Product Offerings
7.15.4 Sanofi Neurologic Disorder Treatment Drug Revenue in Global Market (2018-2023)
7.15.5 Sanofi Key News & Latest Developments
7.16 Takeda Pharmaceutical
7.16.1 Takeda Pharmaceutical Company Summary
7.16.2 Takeda Pharmaceutical Business Overview
7.16.3 Takeda Pharmaceutical Neurologic Disorder Treatment Drug Major Product Offerings
7.16.4 Takeda Pharmaceutical Neurologic Disorder Treatment Drug Revenue in Global Market (2018-2023)
7.16.5 Takeda Pharmaceutical Key News & Latest Developments
7.17 Teva Pharmaceutical Industries
7.17.1 Teva Pharmaceutical Industries Company Summary
7.17.2 Teva Pharmaceutical Industries Business Overview
7.17.3 Teva Pharmaceutical Industries Neurologic Disorder Treatment Drug Major Product Offerings
7.17.4 Teva Pharmaceutical Industries Neurologic Disorder Treatment Drug Revenue in Global Market (2018-2023)
7.17.5 Teva Pharmaceutical Industries Key News & Latest Developments
7.18 UCB
7.18.1 UCB Company Summary
7.18.2 UCB Business Overview
7.18.3 UCB Neurologic Disorder Treatment Drug Major Product Offerings
7.18.4 UCB Neurologic Disorder Treatment Drug Revenue in Global Market (2018-2023)
7.18.5 UCB Key News & Latest Developments
7.19 USWM
7.19.1 USWM Company Summary
7.19.2 USWM Business Overview
7.19.3 USWM Neurologic Disorder Treatment Drug Major Product Offerings
7.19.4 USWM Neurologic Disorder Treatment Drug Revenue in Global Market (2018-2023)
7.19.5 USWM Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Neurologic Disorder Treatment Drug Market Opportunities & Trends in Global Market
Table 2. Neurologic Disorder Treatment Drug Market Drivers in Global Market
Table 3. Neurologic Disorder Treatment Drug Market Restraints in Global Market
Table 4. Key Players of Neurologic Disorder Treatment Drug in Global Market
Table 5. Top Neurologic Disorder Treatment Drug Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Neurologic Disorder Treatment Drug Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Neurologic Disorder Treatment Drug Revenue Share by Companies, 2018-2023
Table 8. Global Companies Neurologic Disorder Treatment Drug Product Type
Table 9. List of Global Tier 1 Neurologic Disorder Treatment Drug Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Neurologic Disorder Treatment Drug Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Neurologic Disorder Treatment Drug Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Neurologic Disorder Treatment Drug Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Neurologic Disorder Treatment Drug Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Neurologic Disorder Treatment Drug Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Neurologic Disorder Treatment Drug Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Neurologic Disorder Treatment Drug Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2024-2029
Table 30. AbbVie Company Summary
Table 31. AbbVie Neurologic Disorder Treatment Drug Product Offerings
Table 32. AbbVie Neurologic Disorder Treatment Drug Revenue (US$, Mn) & (2018-2023)
Table 33. AbbVie Key News & Latest Developments
Table 34. Acadia Pharmaceuticals Company Summary
Table 35. Acadia Pharmaceuticals Neurologic Disorder Treatment Drug Product Offerings
Table 36. Acadia Pharmaceuticals Neurologic Disorder Treatment Drug Revenue (US$, Mn) & (2018-2023)
Table 37. Acadia Pharmaceuticals Key News & Latest Developments
Table 38. Acorda Therapeutics Biotechnology Company Summary
Table 39. Acorda Therapeutics Biotechnology Neurologic Disorder Treatment Drug Product Offerings
Table 40. Acorda Therapeutics Biotechnology Neurologic Disorder Treatment Drug Revenue (US$, Mn) & (2018-2023)
Table 41. Acorda Therapeutics Biotechnology Key News & Latest Developments
Table 42. Bayer Company Summary
Table 43. Bayer Neurologic Disorder Treatment Drug Product Offerings
Table 44. Bayer Neurologic Disorder Treatment Drug Revenue (US$, Mn) & (2018-2023)
Table 45. Bayer Key News & Latest Developments
Table 46. Biogen Company Summary
Table 47. Biogen Neurologic Disorder Treatment Drug Product Offerings
Table 48. Biogen Neurologic Disorder Treatment Drug Revenue (US$, Mn) & (2018-2023)
Table 49. Biogen Key News & Latest Developments
Table 50. CSK Company Summary
Table 51. CSK Neurologic Disorder Treatment Drug Product Offerings
Table 52. CSK Neurologic Disorder Treatment Drug Revenue (US$, Mn) & (2018-2023)
Table 53. CSK Key News & Latest Developments
Table 54. Eisai Company Summary
Table 55. Eisai Neurologic Disorder Treatment Drug Product Offerings
Table 56. Eisai Neurologic Disorder Treatment Drug Revenue (US$, Mn) & (2018-2023)
Table 57. Eisai Key News & Latest Developments
Table 58. F. Hoffmann La Roche Company Summary
Table 59. F. Hoffmann La Roche Neurologic Disorder Treatment Drug Product Offerings
Table 60. F. Hoffmann La Roche Neurologic Disorder Treatment Drug Revenue (US$, Mn) & (2018-2023)
Table 61. F. Hoffmann La Roche Key News & Latest Developments
Table 62. H Lundbeck Company Summary
Table 63. H Lundbeck Neurologic Disorder Treatment Drug Product Offerings
Table 64. H Lundbeck Neurologic Disorder Treatment Drug Revenue (US$, Mn) & (2018-2023)
Table 65. H Lundbeck Key News & Latest Developments
Table 66. Johnson and Johnson Company Summary
Table 67. Johnson and Johnson Neurologic Disorder Treatment Drug Product Offerings
Table 68. Johnson and Johnson Neurologic Disorder Treatment Drug Revenue (US$, Mn) & (2018-2023)
Table 69. Johnson and Johnson Key News & Latest Developments
Table 70. Merck Company Summary
Table 71. Merck Neurologic Disorder Treatment Drug Product Offerings
Table 72. Merck Neurologic Disorder Treatment Drug Revenue (US$, Mn) & (2018-2023)
Table 73. Merck Key News & Latest Developments
Table 74. Novartis Company Summary
Table 75. Novartis Neurologic Disorder Treatment Drug Product Offerings
Table 76. Novartis Neurologic Disorder Treatment Drug Revenue (US$, Mn) & (2018-2023)
Table 77. Novartis Key News & Latest Developments
Table 78. Otsuka Pharmaceutical Company Summary
Table 79. Otsuka Pharmaceutical Neurologic Disorder Treatment Drug Product Offerings
Table 80. Otsuka Pharmaceutical Neurologic Disorder Treatment Drug Revenue (US$, Mn) & (2018-2023)
Table 81. Otsuka Pharmaceutical Key News & Latest Developments
Table 82. Pfizer Company Summary
Table 83. Pfizer Neurologic Disorder Treatment Drug Product Offerings
Table 84. Pfizer Neurologic Disorder Treatment Drug Revenue (US$, Mn) & (2018-2023)
Table 85. Pfizer Key News & Latest Developments
Table 86. Sanofi Company Summary
Table 87. Sanofi Neurologic Disorder Treatment Drug Product Offerings
Table 88. Sanofi Neurologic Disorder Treatment Drug Revenue (US$, Mn) & (2018-2023)
Table 89. Sanofi Key News & Latest Developments
Table 90. Takeda Pharmaceutical Company Summary
Table 91. Takeda Pharmaceutical Neurologic Disorder Treatment Drug Product Offerings
Table 92. Takeda Pharmaceutical Neurologic Disorder Treatment Drug Revenue (US$, Mn) & (2018-2023)
Table 93. Takeda Pharmaceutical Key News & Latest Developments
Table 94. Teva Pharmaceutical Industries Company Summary
Table 95. Teva Pharmaceutical Industries Neurologic Disorder Treatment Drug Product Offerings
Table 96. Teva Pharmaceutical Industries Neurologic Disorder Treatment Drug Revenue (US$, Mn) & (2018-2023)
Table 97. Teva Pharmaceutical Industries Key News & Latest Developments
Table 98. UCB Company Summary
Table 99. UCB Neurologic Disorder Treatment Drug Product Offerings
Table 100. UCB Neurologic Disorder Treatment Drug Revenue (US$, Mn) & (2018-2023)
Table 101. UCB Key News & Latest Developments
Table 102. USWM Company Summary
Table 103. USWM Neurologic Disorder Treatment Drug Product Offerings
Table 104. USWM Neurologic Disorder Treatment Drug Revenue (US$, Mn) & (2018-2023)
Table 105. USWM Key News & Latest Developments
List of Figures
Figure 1. Neurologic Disorder Treatment Drug Segment by Type in 2022
Figure 2. Neurologic Disorder Treatment Drug Segment by Application in 2022
Figure 3. Global Neurologic Disorder Treatment Drug Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Neurologic Disorder Treatment Drug Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Neurologic Disorder Treatment Drug Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Neurologic Disorder Treatment Drug Revenue in 2022
Figure 8. By Type - Global Neurologic Disorder Treatment Drug Revenue Market Share, 2018-2029
Figure 9. By Application - Global Neurologic Disorder Treatment Drug Revenue Market Share, 2018-2029
Figure 10. By Type - Global Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Neurologic Disorder Treatment Drug Revenue Market Share, 2018-2029
Figure 12. By Application - Global Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Neurologic Disorder Treatment Drug Revenue Market Share, 2018-2029
Figure 14. By Region - Global Neurologic Disorder Treatment Drug Revenue Market Share, 2018-2029
Figure 15. By Country - North America Neurologic Disorder Treatment Drug Revenue Market Share, 2018-2029
Figure 16. US Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Neurologic Disorder Treatment Drug Revenue Market Share, 2018-2029
Figure 20. Germany Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2018-2029
Figure 21. France Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Neurologic Disorder Treatment Drug Revenue Market Share, 2018-2029
Figure 28. China Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2018-2029
Figure 32. India Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Neurologic Disorder Treatment Drug Revenue Market Share, 2018-2029
Figure 34. Brazil Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Neurologic Disorder Treatment Drug Revenue Market Share, 2018-2029
Figure 37. Turkey Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Neurologic Disorder Treatment Drug Revenue, (US$, Mn), 2018-2029
Figure 41. AbbVie Neurologic Disorder Treatment Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Acadia Pharmaceuticals Neurologic Disorder Treatment Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Acorda Therapeutics Biotechnology Neurologic Disorder Treatment Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Bayer Neurologic Disorder Treatment Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Biogen Neurologic Disorder Treatment Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. CSK Neurologic Disorder Treatment Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Eisai Neurologic Disorder Treatment Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. F. Hoffmann La Roche Neurologic Disorder Treatment Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. H Lundbeck Neurologic Disorder Treatment Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Johnson and Johnson Neurologic Disorder Treatment Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Merck Neurologic Disorder Treatment Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Novartis Neurologic Disorder Treatment Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Otsuka Pharmaceutical Neurologic Disorder Treatment Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Pfizer Neurologic Disorder Treatment Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. Sanofi Neurologic Disorder Treatment Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 56. Takeda Pharmaceutical Neurologic Disorder Treatment Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 57. Teva Pharmaceutical Industries Neurologic Disorder Treatment Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 58. UCB Neurologic Disorder Treatment Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 59. USWM Neurologic Disorder Treatment Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 神経疾患治療薬の世界市場見通し2023年-2029年(Neurologic Disorder Treatment Drug Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 睡眠障害治療薬の世界市場見通し2023年-2029年

    • ◆H&Iグローバルリサーチのお客様（例）◆